(VIANEWS) – The NASDAQ opens in less than five hours and FibroGen‘s pre-market value is already 6.72% up.
FibroGen’s last close was $17.57, 31.61% under its 52-week high of $25.69.
The last session, NASDAQ ended with FibroGen (FGEN) falling 0.4% to $17.57. NASDAQ dropped 0.24% to $12,657.90, following the last session’s downward trend on what was a somewhat down trend exchanging session.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.27.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -411.93%.
Volume
Today’s last reported volume for FibroGen is 712195 which is 45.67% below its average volume of 907737.
Sales Growth
FibroGen’s sales growth is 15.4% for the present quarter and 138.5% for the next.
More news about FibroGen (FGEN).
